A Single-center, Randomized, Double-blind, Active-controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of 26-valent Pneumococcal Conjugate Vaccine in People Aged 2 Months and Older
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs Pneumococcal conjugate 26 valent vaccine Beijing Zhifei Lvzhu Biopharmaceutical (Primary) ; Pneumococcal polysaccharide 23 valent vaccine Beijing Zhifei Lvzhu Biopharmaceutical (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Beijing Zhifei Lvzhu Biopharmaceutical
- 27 Nov 2024 New trial record